Bayer has entered into a global licensing agreement with Chinese biotech Puhe BioPharma for an oral PRMT5 inhibitor (BAY 3713372) that selectively targets MTAP-deleted tumors, which occur in 10-30% of all cancers.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.